Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Nektar Therapeutics (NASDAQ: NKTR) was $0.88 for the day, down -1.08% from the previous closing price of $0.89. In other words, the price has decreased by -$1.08 from its previous closing price. On the day, 1.49 million shares were traded. NKTR stock price reached its highest trading level at $0.8979 during the session, while it also had its lowest trading level at $0.8708.
Ratios:
Our analysis of NKTR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.24 and its Current Ratio is at 4.24. In the meantime, Its Debt-to-Equity ratio is 4.22 whereas as Long-Term Debt/Eq ratio is at 3.78.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, B. Riley Securities on January 08, 2025, initiated with a Buy rating and assigned the stock a target price of $4.
On December 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $6.50.
On November 04, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $7.Piper Sandler initiated its Overweight rating on November 04, 2024, with a $7 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 23 ’24 when Wilson Mark Andrew sold 33,402 shares for $0.90 per share. The transaction valued at 30,062 led to the insider holds 351,892 shares of the business.
Wilson Mark Andrew sold 16,560 shares of NKTR for $14,738 on Dec 24 ’24. The Chief Legal Officer now owns 335,332 shares after completing the transaction at $0.89 per share. On Dec 24 ’24, another insider, Wilson Mark Andrew, who serves as the Officer of the company, bought 16,560 shares for $0.89 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 163226880 and an Enterprise Value of 124823136. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.75 while its Price-to-Book (P/B) ratio in mrq is 3.34. Its current Enterprise Value per Revenue stands at 1.34 whereas that against EBITDA is -0.959.
Stock Price History:
The Beta on a monthly basis for NKTR is 0.59, which has changed by 0.57142854 over the last 52 weeks, in comparison to a change of 0.23809385 over the same period for the S&P500. Over the past 52 weeks, NKTR has reached a high of $1.93, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is -13.68%, while the 200-Day Moving Average is calculated to be -30.04%.
Shares Statistics:
NKTR traded an average of 1.84M shares per day over the past three months and 1318980 shares per day over the past ten days. A total of 184.46M shares are outstanding, with a floating share count of 177.74M. Insiders hold about 3.64% of the company’s shares, while institutions hold 74.37% stake in the company. Shares short for NKTR as of 1735603200 were 4349151 with a Short Ratio of 2.37, compared to 1732838400 on 4440183. Therefore, it implies a Short% of Shares Outstanding of 4349151 and a Short% of Float of 3.01.
